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Abstract 
Hyperactivity of the hypothalamic pituitary-adrenal (HPA) axis plays a role in the 
pathophysiology of major depressive disorder (MDD). Recent studies suggest the role of the 
glutamatergic system in the pathophysiology of MDD, and N-methyl-D-aspartate (NMDA) 
receptor antagonists have shown antidepressant effects in both preclinical and clinical studies. 
However, little is known about the role of adrenocorticotropic hormone (ACTH) specifically 
in the glutamatergic response to HPA axis activation. Glutamate is an NMDA receptor agonist, 
and glycine and D-serine act as co-agonists. Here, we measured brain concentrations of these 
amino acids in rats given repeated administration of ACTH (100 μg/rat/day, sc, for 14 days). 
Further, we also evaluated behavioral effects of ketamine and memantine, non-competitive 
NMDA antagonists, on immobility time in the forced swimming test and on locomotor 
activity in ACTH-treated rats. Compared with control rats, glutamine, glycine, L-serine, and 
D-serine levels were increased in the hippocampus of ACTH-treated rats; glutamate, 
glutamine, glycine, L-serine, and D-serine were increased in the cerebellum; and glutamine and 
glycine were increased in the frontal cortex and striatum, all with statistical significance. 
Remarkably, these increases in agonists and co-agonists might have lead to the augmentation 
of NMDA receptor activity. ACTH treatment increased immobility time in the forced 
swimming test and decreased locomotor activity in rats. Ketamine (20 mg/kg, ip) did not 
show any effects in these behavioral tests in ACTH-treated rats. On the contrary, memantine 
(10 mg/kg, ip) significantly decreased immobility time in the forced swimming test and 
increased locomotor activity in ACTH-treated rats. These results suggest that depressive-like 
behaviors by chronic ACTH treatment could be blocked by memantine but not ketamine. 
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Abbreviation list: 
MDD, Major depressive disorder; HPA, hypothalamic pituitary-adrenal; CRH, corticotrophin 
releasing hormone; ACTH, adrenocorticotropic hormone; 5-HT, 5-hydroxytryptamine; CNS, 
central nervous system; EAATs, excitatory amino acid transporters; NMDA, 
N-methyl-D-aspartate; TFA, trifluoroacetic acid; HPLC, high performance liquid 
chromatography; ANOVA, one way analysis of variance; GFAP, Glial fibrillary acidic protein; 
TRH, thyrotropin-releasing hormone; WKY, Wistar Kyoto; SD, Sprague-Dawley; BN, 
Brown-Norway; MRI, Magnetic resonance imaging; SSRI, selective serotonin reuptake 
inhibitor. 
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1. Introduction 
Major depressive disorder (MDD), also called major depression, is a chronic recurring 
illness (Kessler and Wang, 2008, Lopez and Mathers, 2006), between one- and two-thirds of 
patients do not respond to the first antidepressant prescribed, and treatment-resistant 
depression represents an area of substantial unmet medical need (Little, 2009, Shelton et al., 
2010). One factor thought to play a role in the symptoms of depression is environmental 
stress-induced hyperactivity of the hypothalamic pituitary-adrenal (HPA) axis (Gillespie and 
Nemeroff, 2005, Mello et al., 2003, Swaab et al., 2005). Stress initiates the release of 
corticotropin-releasing hormone (CRH), followed by that of adrenocorticotropic hormone 
(ACTH), and induces changes in the serotonergic system which involve an increase in the 
expression of 5-hydroxytryptamine (5-HT) 2A receptors (Arango et al., 1990, Arora and 
Meltzer, 1989, Leonard, 2005, Mann et al., 1986, Pandey et al., 2002). Chronic ACTH 
treatment increases the expression of 5-HT2A receptor mRNA in the frontal cortex in rats 
(Kitamura et al., 2008). Moreover, chronic treatment with ACTH disturbs the antidepressant 
effects of the tricyclic antidepressants 
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine (imipramine) and 
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine (desipramine) 
(Kitamura et al., 2002). ACTH-treated rats might exhibit a severe depressive state, in which 
the response to tricyclic antidepressants is impaired. 
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L-glutamic acid (glutamate) is accepted as the major excitatory neurotransmitter in the 
central nervous system (CNS), and glutamine synthesis from glutamate and ammonia occurs 
Fig. 1. Major functional components for glutamatergic neurons and potential targets 
of glutamatergic agents exerting antidepressant-like actions. 
Glutaminase hydrolyzes glutamine to glutamate and ammonia in presynaptic neurons. 
Glutamate is released into the synaptic cleft and stimulates glutamate receptors (kainate 
receptors, NMDA receptors, AMPA receptors, and mGluRs) in postsynapses, presynapses, 
and glial cells. Glutamate is taken up by EAATs on glial cells. Glutamine synthetase 
converts glutamate and ammonia to glutamine, which is transported to presynaptic 
neurons. Glutamatergic agents are considered to act on the numbered targets in the Figure 
as follows targets: (1) NMDA receptor antagonists (ketamine, NR2B subunit antagonists, 
memantine, magnesium, and zinc); (2) positive modulators of AMPA; (3) group I mGluR 
antagonists, group II mGluR antagonists and agonists, and group III mGluR agonists; (4) 
EAAT2 enhancer (ceftriaxone); (5) possible indirect NMDA receptor modulator 
(minocycline); and (6) possible inhibitor of glutamate release, antagonist of NMDA, 
AMPA, and kainate receptors, and potentiator of glutamate uptake (riluzole). AMPA R, 
α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor; NMDA R, 
N-methyl-D-aspartate receptor; mGluR, metabotropic glutamate receptor; EAAT, 
excitatory amino acid transporter; Gln, glutamine; Glu, glutamate; BDNF, brain-derived 
neurotrophic factor; Ca2+, calcium ion. 
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exclusively in glial cells (Hashimoto, 2009, 2011, Tokita et al., 2012) (Fig. 1). Glutamine 
plays major roles in nitrogen and carbon homeostasis, and in the detoxification of ammonia, 
in addition to acting as a precursor for the synthesis of glutamate in specialized excitatory 
neurons (Hashimoto, 2009, 2011, Tokita et al., 2012) (Fig. 1). Glutamate released from 
presynaptic neurons can interact with postsynaptic glutamate receptors, including 
N-methyl-D-aspartate (NMDA) receptors. The released glutamate is taken up by the 
surrounding glial cells via excitatory amino acid transporters (EAATs), converted to 
glutamine, transported back to the presynaptic neurons, and reconverted to glutamate 
(Hashimoto, 2009, 2011, Tokita et al., 2012) (Fig. 1). There is growing evidence that 
glutamate levels are altered in blood, cerebrospinal fluid, and brain of patients with MDD 
(Auer et al., 2000, Block et al., 2009, Hashimoto, 2009, 2011, Hashimoto et al., 2007, Hasler 
et al., 2007, Sanacora et al., 2004, Tokita et al., 2012). Glutamate released from presynaptic 
neurons can interact with postsynaptic glutamate receptors such as NMDA receptors. The 
NMDA receptor has modulatory sites on its subunits (Hashimoto et al., 2005b, Martineau et 
al., 2006). Glycine is converted to L-serine by serine hydroxymethyltransferase, and L-serine 
is converted to D-serine by serine racemase (Hashimoto et al., 2005b, Martineau et al., 2006). 
Endogenous glycine and D-serine act as co-agonists on the glycine binding site on the NMDA 
receptor and co-activate NMDA receptors along with glutamate (Chen et al., 2003, Hashimoto 
et al., 2005b, Martineau et al., 2006, Yang and Svensson, 2008). The change of glycine and 
D-serine levels in plasma and brain of patients with MDD has been investigated in a few 
studies, but no unified view has been obtained (Hashimoto et al., 2007, Mitani et al., 2006, 
Sumiyoshi et al., 2004). 
Several clinical studies have reported that NMDA receptor antagonists showed rapid 
and/or sustained antidepressant effects in patients with treatment-resistant MDD (Berman et 
al., 2000, Preskorn et al., 2008, Zarate et al., 2006). In preclinical animal models, NMDA 
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receptor antagonists have been shown to exert antidepressant-like effects (Eby and Eby, 2010, 
Machado-Vieira et al., 2009, Nowak et al., 2005, Paul and Skolnick, 2003, Skolnick et al., 
2009, Szewczyk et al., 2008, Tokita et al., 2012). A non-competitive NMDA receptor 
antagonist, 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one (ketamine), decreased the 
immobility time in the forced swim test in rats (Engin et al., 2009; Garcia et al., 2008a; Garcia 
et al., 2008b; Li et al., 2010; Yilmaz et al., 2002) and mice (da Silva et al., 2010; Maeng et al., 
2008; Rosa et al., 2003). Another non-competitive NMDA receptor antagonist, 
3,5-dimethyladamantan-1-amine (memantine), also decreased immobility time in the forced 
swimming test, which is widely used for the screening of antidepressants, in rats and mice 
(Almeida et al., 2006, Moryl et al., 1993, Reus et al., 2010, Rogoz et al., 2002). Although 
confirmation of the antidepressant effects of NMDA receptor antagonists requires further 
investigation, direct targeting of NMDA receptor complexes may bring about rapid and 
relatively sustained antidepressant effects (Zarate et al., 2010, Zarate et al., 2006). 
Here, we determined the concentrations of amino acids (glutamate, glutamine, glycine, 
L-serine, and D-serine) in the frontal cortex, hippocampus, striatum, and cerebellum of rats 
receiving repeated administration of ACTH. Moreover, we also evaluated behavioral effects 
of ketamine and memantine on immobility time in the forced swimming test and on 
locomotor activity in ACTH-treated rats. 
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2. Materials and methods 
2.1. Animals 
Male Wistar rats (Japan SLC, Inc., Hamamatsu, Shizuoka, Japan) were used for all 
experiments at age 9 weeks. The numbers of animals per group were set to have the sufficient 
statistical power of 80%. All animals were given food and water ad libitum. They were 
housed in an air-conditioned room at a temperature of 23±2 °C and humidity of 55±10% 
under a 12:12-h light/dark cycle, with lights on at 7:30 a.m. Rats were acclimated to the 
environment for 1 week before the experiments began. All animal experimental procedures 
were approved by the Institutional Animal Care and Use Committee of Astellas Pharma Inc. 
The Tsukuba Research Center of Astellas Pharma Inc. has been awarded Accreditation Status 
by AAALAC International. 
2.2. Drugs 
Synthesized adrenocorticotropic hormone (Cortrosyn® Z, tetracosactide acetate, ACTH 
(1-24)) was purchased as a suspension in vials from Daiichi Sankyo Co., Ltd, Tokyo, Japan. 
Imipramine hydrochloride was purchased from Sigma-Aldrich Co. LLC., St. Louis, MO, 
USA. Ketamine hydrochloride (ketalar®) was purchased from Daiichi Sankyo Co., Ltd, 
Tokyo, Japan. Memantine hydrochloride was purchased from Tocris Bioscience, Bristol, UK. 
Study rats received subcutaneous injection of ACTH suspension at 100 μg in a volume of 200 
μL per day for 14 days. Control rats received saline instead of ACTH. Imipramine, ketamine, 
and memantine were dissolved in saline and intraperitoneally injected at 5 mL/kg body weight. 
Imipramine was administered at 15 mg/kg, ketamine was administered at 20 mg/kg, and 
memantine was administered at 10 mg/kg. 
2.3. Measurement of amino acids in brain regions 
One day after the last administration of ACTH, rats were anaesthetized with 2% 
isoflurane and then euthanized by exsanguination. The brain was removed and the frontal 
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cortex, hippocampus, striatum, and cerebellum were dissected on ice. Tissues were frozen in 
liquid nitrogen and stored at -80 °C until measurement. 
Tissues were homogenized in 1.5 mL of methanol (HPLC grade) on ice. The 
homogenates were centrifuged at 3000g for 6 min at 4 °C, and 20 μL of supernatant was 
evaporated to dryness at 40 °C. To the residue, 20 μL of H2O (HPLC grade), 20 μL of 0.1 M 
borate buffer (pH 8.0), and 60 μL of 50 mM 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F; 
Tokyo Kasei Kogyo Co., Ltd., Tokyo, Japan) in CH3CN (HPLC grade) were added. The 
reaction mixture was then heated to 60 °C for 2 min, and immediately supplemented with 100 
μL of H2O/acetonitrile (90/10) containing 0.1% trifluoroacetic acid (TFA) to stop the reaction. 
Total D- and L-serine levels were measured using a column-switching high performance 
liquid chromatography (HPLC) system (Shimadzu Corporation, Kyoto, Japan), as previously 
reported (Fukushima et al., 2004, Hashimoto et al., 2007, Horio et al., 2011, Yamada et al., 
2005). Glycine, glutamine, and glutamate were measured using an HPLC system with 
fluorescence detection as previously reported (Hashimoto et al., 2005a, Horio et al., 2011). A 
20 μL aliquot of the resulting solution was injected into the HPLC system. A reversed-phase 
ODS column (TSKgel ODS-80Ts (Tosoh Corporation, Tokyo, Japan) as Column 1) was used 
for the separation and quantification of total D- and L-serine, and the gradient elution of the 
mobile phase was maintained at a constant flow rate of 0.8 mL/min. Mobile phase 1a 
consisted of H2O/acetonitrile (90/10) containing 0.1% TFA, and phases 1b and 1c of H2O/ 
acetonitrile (10/90) containing 0.1% TFA and acetonitrile, respectively. The time program for 
gradient elution was as follows: 0–25 min 1a:1b:1c =92:8:0, 25–25.1 min linear gradient from 
8% 1b to 100% 1b, 25.1–35 min 1a:1b:1c =0:100:0, 35–35.1 min linear gradient from 0% 1c 
to 100% 1c, 35.1–40 min 1a:1b:1c =0:0:100, 40–40.1 min linear gradient from 0% 1b to 8% 
1b, and 40.1–60 min 1a:1b:1c =92:8:0. The chiral column (Column 2) used for the separation 
and quantification of D- and L-serine with NBD-F consisted of two Sumichiral OA-2500 
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columns (S) (Sumika Chemical Analysis Service Ltd., Osaka, Japan), which were connected 
in tandem. The mobile phase was 15 mM citric acid in methanol. Flow rate was isocratically 
pumped at 1.0 mL/min, and column temperature was maintained at 35 °C for all columns. 
Fluorescence detection was performed at 530 nm with an excitation wavelength of 470 nm. 
Glycine, glutamine, and glutamate were determined using a reversed-phase ODS column 
(TSKgel ODS-80Ts, Tosoh Corporation, Tokyo, Japan). The gradient elution of the mobile 
phase was kept at a constant flow rate of 0.8 mL/min. The time program for gradient elution 
was programmed as follows: 0–50.5 min 1a:1b:1c =95:5:0, 50.5–55.5 min 1a:1b:1c =0:100:0, 
and 55.5–57 min, 1a:1b:1c =0:0:100. All column temperatures were maintained at 35 °C. 
Fluorescence detection was performed at 530 nm with an excitation wavelength of 470 nm. 
2.4. Forced swimming test 
The forced swimming test was performed according to Porsolt’s method (Castagne et 
al., 2011). A rat was placed in an opaque cylinder (20 cm diameter, 40 cm height) containing 
water (25 cm height, at 24±1 ºC) equipped with a coil current detector near the water surface 
around the cylinder (MicroAct®, Neuroscience, Inc., Tokyo, Japan). The coil current 
generated by the movement of magnets attached to both forepaws of a rat was detected as 
activity of the rat in seeking to escape from the water in the cylinder. The coil currents were 
sampled and analyzed according to the following parameters. The range of amplified and 
transformed voltage was set from 0.05 V to 2.5 V. The range of frequency was set from 7 Hz 
to 15 Hz. The criterion for the splitting of events was set to over 0.2 s. The criterion of a valid 
event was set to over 0.35 s. In the pre-test session, rats were forced to swim for 15 min one 
day after the last administration of ACTH in the case of repeatedly ACTH-treated rats. 
Imipramine, ketamine, and memantine were administered at 15 min after the end of this 
swimming. In the test session, imipramine and ketamine were administered 5 h and 30 min 
before the test, or memantine was administered 2 h before the test. Rats were forced to swim 
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at 24.5 h after the pre-test for 5 min. Immobility time in the test session was obtained as the 
total time (300 s) minus the time in which the rat sought to escape from the water. 
2.5. Locomotor activity 
Activity of a rat was measured in a plastic cage (20.5 cm width, 37.5 cm depth, 20.3 cm 
height) equipped with a passive infrared sensor placed on the board over it (Supermex, 
Muromachi Kikai Co., Ltd., Tokyo, Japan). The movement of the rat was counted with pulse 
data obtained from the sensor as locomotor activity. Rats were evaluated one day after the last 
administration of ACTH. They were placed in plastic cages and their activities were measured 
for 30 min during exposure to the novel environment, beginning 30 min after the 
administration of imipramine and ketamine, or 2 h after that of memantine. 
2.6. Statistical analysis 
All results are expressed as the mean ± SE. Statistical analysis was conducted using 
two-way analysis of variance (ANOVA) followed by post hoc Bonferroni's multiple 
comparison test for evaluation of the effect of imipramine, ketamine, and memantine with or 
without ACTH treatment on immobility time in the forced swimming test and on locomotor 
activity. Student’s t test was used to evaluate the effect of ACTH on levels of amino acids in 
brain regions. P<0.05 was considered statistically significant. All statistical analyses were 
conducted using Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA) and the PASW 
Statitics 20 (formerly SPSS Statistics; SPSS, Tokyo, Japan). 
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3. Results 
Amino acid levels were determined in brain regions of ACTH-treated rats (Table 1). Levels of 
glutamine (t=8.887, P<0.0001), glycine (t=6.194, P=0.0001), L-serine (t=4.374, P=0.0014), 
and D-serine (t=2.585, P=0.0272) were increased in the hippocampus of ACTH-treated rats 
compared to control rats (Table 1). In the cerebellum, glutamate (t=4.687, P=0.0009), 
glutamine (t=6.606, P<0.0001), glycine (t=5.967, P=0.0001), L-serine (t=8.802, P<0.0001), 
and D-serine (t=6.326, P<0.0001) were increased (Table 1). In addition, glutamine and glycine 
were increased in the frontal cortex and striatum (glutamine in frontal cortex: t=5.599, 
P=0.0002, glycine in the frontal cortex: t=4.042, P=0.0024, glutamine in the striatum: t=5.631, 
P=0.0002, glycine in striatum: t=3.604, P=0.0048) (Table 1). Glutamate/glutamine ratios were 
decreased in the frontal cortex (t=3.870, P=0.0031), hippocampus (t=8.415, P<0.0001), and 
striatum (t=6.453, P<0.0001) of ACTH-treated rats (Table 1).  
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Table 1.  Effect of repeated ACTH administration (100 μg/rat/day, sc, 14 days) on levels of glutamate, glutamine, glycine, L-serine, and D-serine  
(nmol/ mg tissue) in the frontal cortex, hippocampus, striatum, and cerebellum in rats 
   Glutamate  Glutamine Glycine  L-serine  D-serine  Glutamate 
             /Glutamine (ratio) 
Frontal cortex 
 Control  8.922 ± 0.556 3.784 ± 0.227 0.557 ± 0.034 0.5128 ± 0.0273 0.2031 ± 0.0112 2.362 ± 0.077 
 ACTH  10.186 ± 0.169 5.222 ± 0.121*** 0.704 ± 0.014** 0.5675 ± 0.0072 0.2055 ± 0.0026 1.958 ± 0.070** 
Hippocampus 
 Control  6.999 ± 0.070 3.429 ± 0.048 0.556 ± 0.008 0.4910 ± 0.0115 0.1806 ± 0.0055 2.043 ± 0.034 
 ACTH  7.235 ± 0.114 4.349 ± 0.092*** 0.647 ± 0.012*** 0.5493 ± 0.0068** 0.1958 ± 0.0020* 1.666 ± 0.029*** 
Striatum 
 Control  7.391 ± 0.155 4.245 ± 0.164 0.481 ± 0.015 0.5100 ± 0.0152 0.1961 ± 0.0051 1.749 ± 0.046 
 ACTH  7.279 ± 0.149 5.313 ± 0.095*** 0.567 ± 0.018** 0.5480 ± 0.0164 0.1963 ± 0.0060 1.372 ± 0.036*** 
Cerebellum 
 Control  5.296 ± 0.096 3.157 ± 0.058 0.406 ± 0.009 0.3723 ± 0.0093 0.0039 ± 0.0000 1.678 ± 0.021 
 ACTH  5.837 ± 0.065*** 3.614 ± 0.038*** 0.475 ± 0.007*** 0.4877 ± 0.0093*** 0.0047 ± 0.0001*** 1.617 ± 0.030 
Data are expressed as the mean ± SE. Six animals were used for each group. *p<0.05, **p<0.01, ***p<0.001 compared to control group 
(Student’s t test). ACTH: adrenocorticotropic hormone 
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The effects of imipramine, ketamine, and memantine with or without ACTH treatment 
were evaluated in the forced swimming test. A two-way ANOVA revealed the effect of ACTH 
[F(1, 64)= 89.40; p<0.0001], drugs [F(3, 64)= 26.27; p<0.0001], and interaction between 
drugs and ACTH [F(3, 64)= 6.618; p=0.0006]. Post hoc analysis showed that acute 
imipramine treatment significantly (P<0.0001) decreased immobility time in the control 
groups (Fig. 2). Acute ketamine treatment significantly (P<0.0001) decreased immobility time 
in the control groups (Fig. 2). Acute memantine treatment significantly (P<0.0001) decreased 
immobility time in the control groups (Fig. 2). Repeated ACTH treatment significantly 
(P<0.01) increased immobility time compared to the vehicle control group (Fig. 2). However 
no change was seen with imipramine treatment in the ACTH-treated groups (P>0.05) (Fig. 2). 
No change was also seen with ketamine treatment in the ACTH-treated groups (P>0.05) (Fig. 
2). Memantine treatment significantly (P<0.001) decreased immobility time in the 
ACTH-treated groups (Fig. 2). 
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The effects of imipramine, ketamine, and memantine with or without ACTH treatment 
on locomotor activity were evaluated. A two-way ANOVA revealed no effect of ACTH [F(1, 
88)= 0.2193; p=0.6407] but drugs [F(3, 88)= 22.58; p<0.0001], and interaction between drugs 
and ACTH [F(3, 88)= 26.27; p<0.0001]. Post hoc analysis showed that acute imipramine 
treatment significantly (P<0.0001) decreased locomotor activity in the control groups (Fig. 3). 
Acute ketamine treatment significantly (P<0.0001) decreased locomotor activity in the control 
groups (Fig. 3). Acute memantine treatment significantly (P<0.001) decreased locomotor 
Fig. 2. Effects of imipramine, ketamine, and memantine with or without ACTH 
treatment on immobility time in the forced swimming test in rats 
ACTH (100 μg/rat/day, sc) was injected for 14 days. The following day the forced 
swimming test was performed. Imipramine (15 mg/kg, ip) and ketamine (20 mg/kg, ip) 
were administered 15 min after the end of swimming in the pre-test session, 5 h before the 
test session, and 30 min before the test session. Memantine (10 mg/kg, ip) was 
administered 15 min after the end of swimming in the pre-test session and 2 h before the 
test session. Data are expressed as the mean ± SE. Eighteen animals were used for each 
vehicle group in control and ACTH treatment, and six animals were used for each other 
group. **p<0.01, ***p<0.001; statistically significant by Two-way ANOVA followed by 
post-hoc test. NS: not significant. ACTH: adrenocorticotropic hormone. Veh: vehicle. Imi: 
imipramine. Ket: ketamine. Mem: memantine. 
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activity in the control groups (Fig. 3). ACTH treatment significantly (P<0.0001) decreased 
locomotor activity compared to the vehicle control group (Fig. 3). Imipramine treatment 
significantly (P<0.01) decreased locomotor activity in the ACTH-treated groups (Fig. 3). 
However no change was seen with ketamine treatment in the ACTH-treated groups (P>0.05) 
(Fig. 3). Memantine treatment significantly (P<0.0001) increased locomotor activity in the 
ACTH-treated groups (Fig. 3). 
 
  
Fig. 3. Effects of imipramine, ketamine, and memantine with or without ACTH 
treatment on locomotor activity in rats 
ACTH (100 μg/rat/day, sc) was injected for 14 days. The following day locomotor activity 
was measured. Imipramine (15 mg/kg, ip) and ketamine (20 mg/kg, ip) were administered 
30 min before the test. Memantine (10 mg/kg, ip) was administered 2 h before the test. 
Data are expressed as the mean ± SE. Twenty four animals were used for each vehicle 
group in control and ACTH treatment, and eight animals were used for each other group. 
**p<0.01, ***p<0.001; statistically significant by Two-way ANOVA followed by post-hoc 
test. ACTH: adrenocorticotropic hormone. Veh: vehicle. Imi: imipramine. Ket: ketamine. 
Mem: memantine. 
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4. Discussion 
In this study, we found that glutamate levels were increased in the cerebellum of 
ACTH-treated rats, that glycine was increased in the frontal cortex, hippocampus, and 
cerebellum of these rats, and that D-serine was increased in the hippocampus and cerebellum. 
ACTH treatment increased immobility time in the forced swimming test and decreased 
locomotor activity in rats. Ketamine did not show any effects in these behavioral tests in 
ACTH-treated rats. On the contrary, memantine decreased immobility time in the forced 
swimming test and increased locomotor activity in ACTH-treated rats. These findings suggest 
that chronic ACTH treatment might change the glutamatergic response blocked by memantine 
but not ketamine. 
Little is known about the role of ACTH specifically in the glutamatergic response to 
HPA axis activation. A major finding of our present study is that repeated ACTH treatment 
affected amino acid levels in rat brain since these amino acids are known to affect the 
neurotransmission via the NMDA receptor (Hashimoto et al., 2007). Glutamate was increased 
in the cerebellum (Table 1). Glycine was increased in the frontal cortex, hippocampus, 
striatum, and cerebellum of ACTH-treated rats (Table 1). D-serine was increased in the 
hippocampus and cerebellum of rats treated with ACTH (Table 1). These elevations of 
glutamate, glycine, and D-serine are thought to augment the activities of NMDA receptors 
through their agonist or co-agonist activities. The melanocortin receptor subtypes that ACTH 
binds to are rarely expressed in brain (Millington, 2006). Further investigation is necessary to 
clarify the mechanism through that ACTH treatment affected these amino acid levels in brain. 
Glutamine is a precursor for the synthesis of glutamate in specialized excitatory 
neurons (Hashimoto, 2009, Hashimoto et al., 2005b) (Fig. 1). Released glutamate is taken up 
by glia, where it is converted to glutamine by glutamine synthetase, transported back to the 
presynaptic neuron, and reconverted to glutamate by glutaminase (Hashimoto, 2009, 
17 
 
Hashimoto et al., 2005b) (Fig. 1). Thus, the glutamate-glutamine cycle plays a role in 
neuron-glia communication in the synapse (Hashimoto, 2009, Hashimoto et al., 2005b) (Fig. 
1). The pathophysiology of MDD likely involves abnormalities in glutamate-glutamine 
cycling in the brain (Hashimoto, 2009, Valentine and Sanacora, 2009). Chronic ACTH 
treatment induced an increase in glutamine and decrease in the ratio of glutamate/glutamine in 
the frontal cortex, hippocampus, and striatum (Table 1). The glutamate-glutamine cycle 
between neurons and glia cells could have been changed by repeated ACTH treatment. 
Especially increasing glutamine level might be caused by some kind of glial change, which 
warrants further investigation about the effect of ACTH treatment on glia. Glial fibrillary 
acidic protein (GFAP), a specific marker for astrocytes, was reduced in cerebellum of patients 
with MDD (Fatemi et al., 2004). The expression levels of glutamine synthetase were 
decreased or unchanged in some brain regions of MDD patients (Beasley et al., 2006, 
Choudary et al., 2005, Karolewicz et al., 2009, Miguel-Hidalgo et al., 2010). The role of glia 
cells in the pathophysiology of MDD should be studied more. 
Repeated treatment with ACTH induced significant increases in immobility time in the 
forced swimming test (Fig. 2). Kitamura and colleagues reported that ACTH treatment for 14 
days did not affect immobility time in the rat forced swimming test (Kitamura et al., 2002). 
The reason for this discrepancy between our present data and Kitamura’s data is unclear, but 
may involve differences in breeding conditions during ACTH treatment or in experimental 
procedures in the forced swimming test. The ACTH-induced increases in immobility time 
might have been at least in part due to decreases in locomotor activity (Fig. 3). Acute 
administration of ACTH dose-dependently decreased locomotor activity in rats pre-treated 
with dexamethasone (Reddy and Kulkarni, 1998). In contrast, intracerebroventricular 
administration of prepro-thyrotropin releasing hormone (TRH) 178-199, a peptide with 
ACTH release-inhibiting properties, induced an increase in locomotor activity in rats 
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(McGivern et al., 1997). Wistar Kyoto (WKY) rats, a line derived from Wistar rats, are a 
genetic animal model that exhibits depressive behaviors (Malkesman and Weller, 2009). 
WKY lines exhibited significantly longer immobility time in the forced swimming test and 
higher levels of plasma ACTH than a control line of Wistar rats (Malkesman et al., 2006). 
Among WKY, Lewis, and Sprague-Dawley (SD) rats, acute immobilization stress-induced 
increase in plasma ACTH was most enhanced in WKY rats (Pardon et al., 2002). This strain 
also exhibited the lowest level of locomotor activity among the three in a novel open-field 
environment (Pardon et al., 2002), and showed reduced locomotor activity in a novel 
environment and high ACTH levels in plasma compared to Brown-Norway (BN) rats 
regardless of age (Tizabi et al., 1992). Furthermore, prepubertal WKY rats exhibited higher 
levels of anxiety behavior, such as freezing behavior, than controls (Malkesman et al., 2005). 
These findings may indicate that low locomotor activity is observed in certain exacerbated 
depressive conditions and connected to disturbance of the HPA axis. Given the difficulty in 
discriminating depressive or anxiety behavior from generalized motor impairment, the present 
results point to the possibility that the chronic activation of the HPA axis induced by repeated 
ACTH treatment produces the depressive-like state and/or motoric change in rats. 
The cerebellum is responsible for motor coordination. All amino acids measured in the 
present study were increased in the cerebellum of rats treated by ACTH (Table 1). Chronic 
ACTH treatment might modify motoric function in the cerebellum. Magnetic resonance 
imaging (MRI) studies reported that structural deficits in the cerebellum were associated with 
depressive symptoms (Escalona et al., 1993, Lin et al., 2012, Liu et al., 2010, Pillay et al., 
1997). Notably, the volume of cerebellum was decreased in the MDD patients who had not 
responded to the treatment with 
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine (fluoxetine), a selective 
serotonin reuptake inhibitor (SSRI) (Pillay et al., 1997). GFAP was reduced in the cerebellum 
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of patients with MDD (Fatemi et al., 2004). Focusing on the role of the cerebellum may 
become important in characterizing the pathophysiology of refractory MDD. 
We evaluated the effects of imipramine on immobility time in the forced swimming test 
and on locomotor activity to confirm that an antidepressant works in our behavioral models. 
In control rats, imipramine decreased immobility time in the forced swimming test (Fig. 2), 
and also decreased locomotor activity (Fig. 3). A number of experiments have shown that 
imipramine decreases locomotor activity in rodents (Diniz et al., 2011, Hughes and Pither, 
1987, Martin et al., 1982, Meltzer and Fox, 1971, Teixeira et al., 2000). At least, the 
imipramine-induced decrease in immobility time did not stem from any increase in locomotor 
activity. Therefore, the decreased immobility time is considered to be due to its antidepressant 
effect. In ACTH-treated rats, imipramine did not show any change in the forced swimming 
test (Fig. 2) while imipramine decreased locomotor activity (Fig. 3). The motoric modification 
by imipramine is thought to have insignificant impact on the immobility time in the forced 
swimming test. Repeated ACTH treatment for 14 days negated the antidepressant effect of 
imipramine, as was also reported by Kitamura and colleagues (Kitamura et al., 2002, 
Kitamura et al., 2008). Acute imipramine treatment reduced immobility time in the forced 
swimming test in BN and SD rats but not in WKY rats (Lahmame et al., 1997). ACTH-treated 
rats appear to resemble WKY rats in some respects, including a poor response to imipramine. 
The levels of amino acids were altered in brain regions of ACTH-treated rats (Table 1). 
However, further exploration is needed to elucidate a link between changing amino acid levels 
and masking the antidepressant effect of imipramine. 
Ketamine decreased the immobility time in the forced swim test in control rats as is the 
case with results in several laboratories (Engin et al., 2009; Garcia et al., 2008a; Garcia et al., 
2008b; Li et al., 2010; Yilmaz et al., 2002) (Fig. 2), and decreased locomotor activity (Fig. 3). 
Ketamine was thought to exert its antidepressant-like effect despite its motoric effects. 
20 
 
However, ketamine did not affect immobility time in the forced swimming test in rats after 
chronic ACTH treatment just as imipramine did not (Fig. 2). The antidepressant-like effect of 
ketamine seems to have disappeared like that of imipramine. No effect of ketamine was also 
seen on locomotor activity in ACTH-treated rats although imipramine even show the 
decreasing effect on locomotor activity after ACTH-treatment (Fig. 3). Chronic ACTH 
treatment might strongly inhibit the behavioral effects of ketamine, however the reason is 
unknown. 
Consistent with previous observations (Moryl et al., 1993, Reus et al., 2010, Rogoz et 
al., 2002), we found that memantine decreased immobility time in the forced swimming test 
in control rats (Fig. 2), and decreased locomotor activity (Fig. 3). The motoric effect of 
memantine appears to be limited on immobility time in the forced swimming test in control 
rats. Namely, memantine demonstrated its antidepressant-like effect in control rats as well as 
imipramine did. Additionally, memantine showed the decreasing effect on immobility time in 
the forced swimming test in rats treated with ACTH for 14 days where imipramine did not 
(Fig. 2). However, memantine showed the increasing effect on locomotor activity in 
ACTH-treated rats (Fig. 3). The memantine-induced activity might reflect the decreasing 
effect on immobility time in the forced swimming test. Memantine countered the increase in 
immobility time (Fig. 2) and the decrease in locomotor activity (Fig. 3) induced by 
ACTH-treatment. Remarkably, memantine increased locomotor activity in ACTH-treated rats 
while decreasing it in the control rats (Fig. 3). The likely explanation is that memantine 
improved the motoric disturbance via inhibiting NMDA receptor activation enhanced by 
increase in levels of agonists and co-agonists for NMDA receptors. That is to say, NMDA 
receptors have relevant to the motoric disturbance induced by repeated ACTH treatment. 
Recently, memantine administration showed the increase in locomotor activity in the 
7-methoxy-1-methyl-3,4-dihydro-2H-pyrido[3,4-b]indole (harmaline)-treated rats, which are 
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thought to be a model of transient action tremor with locomotor activity decreased (Iseri et al., 
2011). Furthermore, memantine prevented the harmaline-induced neurodegeneration in the 
cerebellum. Memantine can improve the locomotor deficits via blocking the injury in 
cerebellum. In the cerebellum, both of agonists and co-agonists for NMDA receptors were 
increased (Table 1). These findings indicate that activating NMDA receptors in the cerebellum 
may account for the locomotor deficit in ACTH-treated rats.  
 
 
 
 
Two NMDA receptor antagonists acted differently in ACTH-treated rats in spite of the 
same effect in control rats. Memantine counteracted the effects of ACTH in the forced 
swimming test and locomotor activity (Table 2). Conversely, the effects of ketamine were 
cancelled by ACTH treatment (Table 2). Memantine and ketamine can bind at the deep site of 
NMDA receptors however memantine, but not ketamine, can bind at the superficial site 
(Kotermanski et al., 2009). Memantine is a strong voltage-dependent antagonist but ketamine 
is a less voltage-dependent one (Gilling et al., 2009). A randomized, double-blind, 
 
Control rats ACTH-treated rats 
Immobility time Activity Immobility time Activity 
ACTH n/a n/a ↑ ↓ 
Imipramine ↓ ↓ ↔ ↓ 
Ketamine ↓ ↓ ↔ ↔ 
Memantine ↓ ↓ ↓ ↑ 
n/a: not applicable. 
Table 2.  Summary of behavioral effects of imipramine, ketamine, and memantine 
with or without ACTH treatment 
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placebo-controlled, three-way crossover trial in healthy male volunteers showed that ketamine 
significantly increased serum prolactin and cortisol levels, whereas memantine and placebo 
did not affect hormone levels (Hergovich et al., 2001). Cold water swim stress reduced the 
antiseizure efficacies of MK-801 and memantine without affecting phencyclidine and 
ketamine in mice (Deutsch et al., 1997). Adaptive changes in the NMDA receptor complex is 
considered to occur in response to exposure to stress, however stress does not result in a 
simple reduction in the number of activated or open channels, but rather may alter their size or 
charge characteristics (Deutsch et al., 1997). Thus, memantine and ketamine have different 
properties about the binding with NMDA receptors, effects on hormone levels, and antiseizure 
effects in a stressful situation. In the present study, ACTH treatment might plasticize NMDA 
receptors, to which memantine but not ketamine could interact. However, further investigation 
is necessary. 
The cerebellum regulates mood and emotion other than balance and motor control 
(Baldacara et al., 2008, Konarski et al., 2005, Schmahmann et al., 2007). Co-agonists were 
also increased in hippocampus and frontal cortex of ACTH-treated rats (Table 1). It is of 
interest whether ACTH-treated rats have affective abnormality. We have tried to evaluate 
anhedonia-like behavior with the sucrose preference test in ACTH-treated rats. However, we 
failed to measure sucrose preference because ACTH-treated rats showed increase in the total 
consumption of water and sucrose solution (data not shown). Other good methods would be 
demanded to evaluate affective behavior in ACTH-treated rats. Importantly, the low response 
rate to existing antidepressants is an area of unmet medical need (Little, 2009, Shelton et al., 
2010). Given the interest in functional proteins related to glutamate signal transduction as 
potential targets for a new generation of antidepressants (Hashimoto, 2009, 2011, Tokita et al., 
2012), ACTH-treated animals may be useful to assess glutamatergic effects of other types of 
compounds with possibly higher efficacy than existing antidepressants. 
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In summary, this study showed that glutamate levels were increased in the cerebellum 
of ACTH-treated rats, that glycine was increased in the frontal cortex, hippocampus, and 
cerebellum of these rats, and that D-serine was increased in the hippocampus and cerebellum. 
ACTH treatment increased immobility time in the forced swimming test and decreased 
locomotor activity in rats. Ketamine did not show any effects in these behavioral tests in 
ACTH-treated rats. On the contrary, memantine decreased immobility time in the forced 
swimming test and increased locomotor activity in ACTH-treated rats. Taken together, these 
findings suggest that chronic ACTH treatment alters the glutamatergic neurotransmission in 
rat brain, and that depressive-behaviors after chronic ACTH treatment could be blocked by 
memantine but not ketamine. 
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